Evaluation of the tolerability of rivastigmine patch on patients with Alzheimer's disease

Not Applicable

• Conditions: Alzheimer' s disease

• Registration Number: JPRN-UMIN000012372
• Lead Sponsor: Graduate School of Medicine, Osaka City University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-11-22
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

Not provided

Exclusion Criteria

1)patents who have the problem of urination 2)patients who have the skin disease 3)patients who have sight and hearing handicaps and an advanced speech impediment 4)patient whom the principal investigator or subinvestigator judged to be unsuitable as an object of this research

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The evaluation of the safety, tolerability and adverse event(frequency of nausea and vomit, change of dietary intake) of rivastigmine patch in patients who titrated at short interval to the maintenace dose

Secondary Outcome Measures

Name	Time	Method
ADAS-J cog MMSE Medication compliance Change of caregiver burden